Postmenopausal Hormone Therapy and Lung Cancer Risk in the Cancer Prevention Study II Nutrition Cohort
- Carmen Rodriguez,
- Heather Spencer Feigelson,
- Anusila Deka,
- Alpa V. Patel,
- Eric J. Jacobs,
- Michael J. Thun and
- Eugenia E. Calle
- Epidemiology and Surveillance Research, American Cancer Society, National Home Office, Atlanta, Georgia
- Requests for reprints:
Carmen Rodriguez, Epidemiology and Surveillance Research, American Cancer Society, National Home Office, 250 Williams Street Northwest, Atlanta, GA 30303. Phone: 404-329-7796; Fax: 404-327-6450. E-mail: crodrigu{at}cancer.org
Abstract
Background: Studies of postmenopausal hormone therapy and lung cancer incidence have reported positive, negative, and null associations. Most of these studies, however, have had limited ability to control rigorously for cigarette smoking or to examine risk separately by smoking status.
Methods: We examined the association between postmenopausal hormone therapy and lung cancer incidence by smoking status among 72,772 women in the Cancer Prevention Study II Nutrition Cohort. Proportional hazards modeling was used to calculate rate ratios (RR).
Results: During follow-up from 1992 to 2003, we identified 659 cases of incident lung cancer. Current use of any postmenopausal hormone therapy was significantly associated with decreased risk of incident lung cancer [multivariate RR, 0.76; 95% confidence interval (95% CI), 0.62-0.92]. Similar risk estimates were observed for unopposed estrogen use (RR, 0.76; 95% CI, 0.60-0.94) and for estrogen plus progestin (RR, 0.76; 95% CI, 0.57-1.01). Risk associated with current use of postmenopausal hormone therapy was decreased among never smokers (RR, 0.56; 95% CI, 0.33-0.95) as well as current smokers (RR, 0.76; 95% CI, 0.55-1.05) and former smokers (RR, 0.76; 95% CI, 0.58-0.99). Former hormone use was not associated with lung cancer. No trend with duration of hormone use was detected.
Conclusion: These results support the hypothesis that postmenopausal hormone therapy is associated with reduced risk of lung cancer, although the absence of a dose-response relationship weakens the evidence for causality. (Cancer Epidemiol Biomarkers Prev 2008;17(3):655–60)
Footnotes
-
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
-
- Accepted December 19, 2007.
- Received October 10, 2007.
- Revision received December 13, 2007.
